GlassScriptPhysician profile
Matthew J Mccarty
NPI 1184694333
$19,669.31
in general payments reported to CMS, 2019-2025
67 companies · $3,263 in 2025
The $3,263 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,653 · 2020: $1,614 · 2021: $2,809 · 2022: $3,003 · 2023: $3,038 · 2024: $3,290 · 2025: $3,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,716 · Long Term Medical Supply Or Device Loan: $499 · Consulting Fee: $350 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,716.27 |
| Long Term Medical Supply Or Device Loan | $498.50 |
| Consulting Fee | $350.00 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,976.62 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,527.34 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Celgene Corporation | $1,304.17 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $1,177.03 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| Amgen INC. | $1,086.68 | 2019-2023 | Lumakras, Kyprolis, Xgeva |
| Seagen INC. | $874.54 | 2019-2023 | Adcetris, Tukysa |
| Genzyme Corporation | $868.46 | 2019-2025 | |
| Pfizer INC. | $756.57 | 2019-2025 | |
| Genentech USA, INC. | $750.20 | 2019-2025 | Venclexta, Perjeta, Phesgo |
| Alexion Pharmaceuticals, INC. | $729.94 | 2019-2024 | Ultomiris |
| Incyte Corporation | $655.56 | 2019-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $635.71 | 2019-2025 | Keytruda, Welireg |
| Janssen Biotech, INC. | $635.12 | 2019-2025 | Tecvayli, Rybrevant, Imbruvica |
| Exelixis INC. | $482.44 | 2019-2024 | Cabometyx |
| Gilead Sciences, INC. | $440.74 | 2019-2025 | Trodelvy |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $415.38 | 2019-2025 | |
| Daiichi Sankyo INC. | $373.87 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Glaxosmithkline, LLC. | $370.24 | 2020-2025 | Ojjaara, Jemperli, Blenrep |
| Regeneron Healthcare Solutions, INC. | $318.33 | 2019-2025 | Libtayo |
| Astellas Pharma US INC | $316.92 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Abbvie INC. | $299.77 | 2020-2025 | |
| Eisai INC. | $288.62 | 2019-2025 | |
| Lilly USA, LLC | $247.64 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Aveo Pharmaceuticals, INC. | $223.61 | 2023-2025 | Fotivda |
| Takeda Pharmaceuticals U.S.A., INC. | $177.81 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Puma Biotechnology, INC. | $170.05 | 2019-2025 | |
| Intuitive Surgical, INC. | $165.54 | 2024 | |
| Emd Serono, INC. | $163.10 | 2019-2023 | Bavencio |
| Taiho Oncology, INC. | $148.81 | 2019-2023 | |
| Beigene USA, INC. | $147.96 | 2020-2025 | Brukinsa |
| Kite Pharma, INC. | $147.30 | 2020-2024 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.32 | 2019-2025 | Gilotrif |
| Array Biopharma INC | $122.08 | 2021-2025 | Braftovi, Lorbrena, Mektovi |
| Ipsen Biopharmaceuticals, INC | $119.60 | 2019-2024 | Onivyde, Tazverik |
| Mirati Therapeutics, INC. | $109.45 | 2023-2024 | Krazati |
| Pharmacosmos Therapeutics INC. | $105.02 | 2020-2025 | Monoferric |
| Comsort, INC | $100.00 | 2019 | |
| Epizyme, INC. | $96.50 | 2020-2022 | |
| Kyowa Kirin, INC. | $78.57 | 2022-2025 | Poteligeo |
| Karyopharm Therapeutics INC. | $71.08 | 2023-2025 | Xpovio |
| Rigel Pharmaceuticals, INC. | $66.66 | 2022-2023 | Tavalisse, Rezlidhia |
| Deciphera Pharmaceuticals INC. | $64.67 | 2025 | Qinlock, Romvimza |
| Tempus Ai, INC | $62.78 | 2025 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $59.72 | 2020-2025 | |
| Myriad Genetic Laboratories, INC. | $51.23 | 2021-2023 | Myrisk |
| Pharmacyclics LLC, An Abbvie Company | $49.05 | 2019 | |
| Sun Pharmaceutical Industries INC. | $48.00 | 2024-2025 | |
| Iovance Biotherapeutics, INC. | $40.69 | 2025 | Amtagvi |
| Verastem, INC. | $38.89 | 2019 | |
| Sobi, INC | $37.50 | 2022-2024 | |
| Blue Earth Diagnostics | $34.59 | 2021 | |
| Acceleron Pharma, INC. | $33.36 | 2020-2021 | |
| Agios Pharmaceuticals, INC. | $29.52 | 2019-2025 | Pyrukynd |
| Genmab U.S., INC. | $21.96 | 2024 | Epkinly |
| Morphosys, US INC. | $19.03 | 2023 | Monjuvi |
| Tesaro, INC. | $18.29 | 2019 | |
| Apellis Pharmaceuticals, INC. | $17.89 | 2024 | Empaveli |
| Abbott Laboratories | $17.66 | 2021 | |
| Recordati_rare_diseases_inc. | $17.65 | 2025 | Enjaymo |
| Syndax Pharmaceuticals, INC. | $17.54 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.02 | 2022 | |
| Dova Pharmaceuticals | $16.66 | 2019 | |
| Blueprint Medicines Corporation | $16.66 | 2024 | Ayvakit |
| Caris Mpi, INC. | $16.31 | 2025 | Mi Cancer Seek |
| Foundation Medicine, INC. | $15.27 | 2020 | |
| Amag Pharmaceuticals, INC. | $14.08 | 2019 | |
| Fortovia Therapeutics, INC. | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.